Investor Relations

News Releases

Date Title
11/16/17
Summary ToggleKemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA All Clinical and Non-Clinical Programs Remain on Track for ADHD Prodrug Candidate,  Pivotal Efficacy Trial to Study Duration of Therapy to Initiate Prior to Year-End CORALVILLE, Iowa , Nov. 16, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company
11/09/17
Summary ToggleKemPharm Reports Third Quarter 2017 Results and Provides Corporate Update Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Filed IND for KP484, A Super-Extended Release ADHD Methylphenidate Prodrug Product Candidate --  KP484 IND Review Completed by FDA ; Cleared to Proceed to Clinical
11/06/17
Summary ToggleKemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511 Asalhydromorphone’s Physicochemical and Pharmacological Attributes May Offer the Potential to Provide Significant Pain Relief with the Potential of Reduced Opioid Abuse and Misuse CORALVILLE, Iowa , Nov. 06, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc , a clinical-stage specialty pharmaceutical company
11/02/17
Summary ToggleKemPharm’s KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies KP484 Designed to be a Predictably Dosed, “ Super-Extended” Release, Methylphenidate Product Candidate CORALVILLE, Iowa , Nov. 02, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc , a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced
11/01/17
Summary ToggleKemPharm, Inc. to Report Third Quarter 2017 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  November 9, 2017 , 4:30 p.m. ET CORALVILLE, Iowa , Nov. 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary
10/04/17
Summary ToggleKemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD Agreement May Lead to Addition of New Drug Product Candidate and Indication to KemPharm’s Prodrug Development Pipeline CORALVILLE, Iowa , Oct. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
09/20/17
Summary ToggleKemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate KP484 Designed to be a Predictably Dosed, Super-Extended Release, Methylphenidate Product CORALVILLE, Iowa , Sept. 20, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, 
09/12/17
Summary ToggleKemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA FDA Has Assigned a PDUFA Action Date of February 23, 2018 Conference Call and Live Audio Webcast Today at 8:30 a.m. ET CORALVILLE, Iowa , Sept. 12, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
08/31/17
Summary ToggleKemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference CORALVILLE, Iowa , Aug. 31, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,  announced today that its President and Chief Executive Officer, Travis C.
08/10/17
Summary ToggleKemPharm, Inc. Reports Second Quarter 2017 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Clinical Development & Regulatory Highlights : KP415.109 Pharmacokinetics Phase 1 Trial Completed Held KP415 End-of-Phase 1 Meeting with U.S. Food and Drug Administration ( FDA ) Initiated
08/10/17
Summary ToggleKemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial Phase I Study Results Demonstrated Early Peak Exposure to d-Methylphenidate followed by Sustained Duration in both Single and Multiple Dose Settings CORALVILLE, Iowa , Aug. 10, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the
08/08/17
Summary ToggleKemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety Study Confirms Intranasal Abuse of Hydrocodone/Acetaminophen by Adolescents & Adults may be a Significant Public Health Issue CORALVILLE, Iowa , Aug. 08, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and
08/03/17
Summary ToggleKemPharm to Present at Canaccord Genuity 37th Annual Growth Conference CORALVILLE, Iowa , Aug. 03, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C.
08/01/17
Summary ToggleKemPharm, Inc. to Report Second Quarter 2017 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for August 10, 2017 , 4:30 p.m. ET CORALVILLE, Iowa , Aug. 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary
06/28/17
Summary ToggleKemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate KP415 End-of-Phase 1 Meeting with FDA Affirms KemPharm’s Development Plan and Potential NDA Submission as early as late 2018 Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET CORALVILLE, Iowa , June 28, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc.
06/26/17
Summary ToggleKemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone US Patent and Trademark Office issues patent protection to KP746, an investigational therapy for the treatment of pain with a prodrug of oxymorphone CORALVILLE, Iowa , June 26, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the
06/09/17
Summary ToggleKemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids Poster Presentation Highlights Intranasal Abuse Deterrence Technology CORALVILLE, Iowa , June 09, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, will present clinical data
06/01/17
Summary ToggleKemPharm Announces Addition to Leadership Team Andrew Barrett , Ph.D., appointed Vice President, Scientific Affairs CORALVILLE, Iowa , June 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an addition to
05/10/17
Summary ToggleKemPharm, Inc. Reports First Quarter 2017 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Clinical Development & Regulatory Highlights : Reported Positive Data from Proof-of-Concept Phase 1 Intranasal Pharmacokinetic Study of KP511 Announced Additional U.S.
05/01/17
Summary ToggleKemPharm, Inc. to Report First Quarter 2017 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for May 10, 2017 , 4:30 p.m. ET CORALVILLE, Iowa , May 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary